AKBA
Closed
Akebia Ther
3.57
-0.07 (-1.92%)
Last Update: 01 Jul 2025 23:15:00
Yesterday: 3.64
Day's Range: 3.49 - 3.68
Send
sign up or login to leave a comment!
When Written:
0.5604
Akebia Therapeutics is a biopharmaceutical company that focuses on developing and commercializing therapeutics for patients with kidney disease. The company's lead product candidate is vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that is designed to mimic the body's natural response to hypoxia and stimulate the production of erythropoietin, which is a hormone that regulates red blood cell production. Vadadustat is currently in Phase 3 clinical development for the treatment of anemia associated with chronic kidney disease. Akebia is also developing other product candidates for the treatment of various kidney diseases, including diabetic nephropathy and IgA nephropathy. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








